Close Menu

Memorial Sloan-Kettering

Baselga Resigns

Memorial Sloan Kettering Cancer Center's José Baselga has resigned following revelations he did not properly disclose industry ties in research articles.

The tool, called Cerebro, significantly outperformed other publicly available methods, including in the less-trafficked areas of the genome that are now relevant for TMB immunotherapy prediction.

Disclosure Failure

The New York Times reports that José Baselga, chief medical officer at Memorial Sloan Kettering Cancer Center, didn't always disclose industry ties.

MSKCC investigators showed that truncated mRNAs can inactivate tumor suppressor genes, fueling cancer development even without the presence of DNA mutations.

In a pair of commentaries, researchers critique last year's paper reporting the use of CRISPR/Cas9 to correct a mutation in viable human embryos.

Stat News reports that IBM's Watson supercomputer sometimes gives inappropriate cancer treatment advice.

In Cell this week: structural variants affecting regulatory loci in prostate cancer, immune features in the breast cancer microenvironment, and more.

In Nature this week: genomic analysis of ducks, whole-genome doubling among tumor samples, and more.

Researchers looked at the prevalence and effects of whole-genome duplication events across cancers using targeted sequenced data for almost 10,000 advanced cases.

Researchers analyzed germline mutations in 256 kidney cancer patients and found mutations that would have been missed, including therapeutically relevant ones.

Pages

NPR says the explosion and fire earlier this week at a Russian lab that stores dangerous pathogens revives the question of whether such samples should be kept.

According to Wired, Nebula Genomics is providing a way for people to get their genomes sequenced anonymously.

A 26-year-old woman tells Cosmopolitan about learning her APOE status at a young age.

In Science journals this week: a functional genomic screen uncovers drug combination that increases KRAS inhibitor efficacy in aggressive lung cancer, and more.